A Multicenter Clinical Trial of Urine DNA Testing for Bladder Cancer in China
A Multicenter, Single-blind, Observational Clinical Trial of URISAFE
Creative Biosciences (Guangzhou) Co., Ltd.
482 participants
Mar 9, 2022
OBSERVATIONAL
Conditions
Summary
The primary objective of this study is to assess the safety and effectiveness of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) for help diagnose bladder cancer by comparing with clinical standard method (includes medical imaging (MRI, CT, etc.), cystoscopy, pathological examination).
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Urine specimen will be collected by the subject for the detection of Human Multigene Methylation Detection Kit (Fluorescent PCR Method)
Subjects will undergo medical imaging and/or cystoscopy and/or pathological examination
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05337189